All In Biotech

Drug Trial Radar · NCT07514975

First-In-Human Study of KHN922 for Injection

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Apr 2028

Study completion Apr 2029

Sponsor

Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumors Cancer

Interventions

  • KHN922 for injectionDrug

    KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens,intravenous (IV) administration every three weeks (D1) .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Objective Response Rate (ORR)Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.